LB Pharmaceuticals is a New York drug developer focused on LB-102, a candidate for schizophrenia and mood disorders. LBRX reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (5 buy, 1 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 9 | Canaccord Genuity | Initiated | Buy | |
| Oct 6 | Guggenheim | Initiated | Buy | |
| Oct 5 | Roth Capital | Downgrade | Hold | |
| Oct 2 | Needham | Initiated | Buy | |
| Aug 24 | HC Wainwright & Co. | Target raised | Buy |
Whale Options Flow
90DNo whale options trades in LBRX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LBRX is in one of them and how their past LBRX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered LBRX in an article yet. Here's the latest on the wider market.
About LB Pharmaceuticals
LB Pharmaceuticals is a biopharmaceutical company based in New York that develops treatments for neuropsychiatric disorders. Its main product candidate, LB-102, is in late-stage testing for schizophrenia and bipolar depression, with a planned study in major depressive disorder as a supplemental treatment. LB-102 is a chemical relative of amisulpride, an antipsychotic already used in many countries outside the United States. The company aims to offer its treatments to patients and to the psychiatrists who prescribe for them.
- Headquarters
- New York, NY